Supriya Lifescience Limited

SUPRIYA

INE07RO01027

Pharmaceuticals

End-of-day quote NSE India S.E. Other stock markets 03:30:00 11/07/2024 am IST			5-day change	1st Jan Change
398.4 ^INR	-1.01%		-2.94%	+26.56%

14/06	Supriya Lifescience CEO Retires	MT
14/06	Supriya Lifescience Limited Announces Resignation of Rajeev Kumar Jain as Chief Executive Officer	CI

Supriya Lifescience Limited Recommends Final Dividend for the Fiscal 2024

May 28, 2024 at 06:38 pm IST

Supriya Lifescience Limited recommended the final dividend of INR 0.80 per equity share (face value of INR 2 each) subject to approval of shareholders in the upcoming Annual General Meeting.

Latest news about Supriya Lifescience Limited

Supriya Lifescience CEO Retires	14/06	MT
Supriya Lifescience Limited Announces Resignation of Rajeev Kumar Jain as Chief Executive Officer	14/06	CI
Supriya Lifescience Limited Approves Executive Changes	28/05	CI
Supriya Lifescience Limited Recommends Final Dividend for the Fiscal 2024	28/05	CI
Supriya Lifescience Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	28/05	CI
Supriya Lifescience Limited Reports Earnings Results for the Full Year Ended March 31, 2024	28/05	CI
Supriya Lifescience Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	07/02	CI
Supriya Lifescience Limited Announces Approval of Capital Expenditure at Ambernath Site for CDMO Facility	07/02	CI
Supriya Lifescience Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	07/02	CI
Supriya Lifescience Gets Brazil's Health Authority's GMP Certification for Site in India	05/01	MT
Supriya Lifescience Ltd Signs Agreement with Kalinga Institute of Technology for Further Development of Wound Healing Gel	06/11	CI
Supriya Lifescience Ties Up with Kalinga Institute for Oral Cancer Detection Kit	24/23/24	MT
Supriya Lifescience Ltd Collaborates with Kalinga Institute of Industrial Technology to Develop One of its Kind Oral Cancer Detection Kit Named Quickblue Oral Kit	23/23/23	CI
Supriya Lifescience Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	03/23/03	CI
Supriya Lifescience Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	03/23/03	CI
Supriya Lifescience Ltd. and Plasma Nutrition, Inc Announce Collaboration in Protein Technology	02/23/02	CI
Supriya Lifescience Limited Executes A Long-Term Supply and Sales Agreement with A Leading Company in Europe for the Supply of Active Pharmaceutical Ingredient	29/23/29	CI
Supriya Lifescience Limited Recommends Final Dividend for the Year Ended March 31, 2023	26/23/26	CI
Supriya Lifescience Names President for Business Development, Strategy and R&D	26/23/26	MT
Supriya Lifescience Limited Reports Earnings Results for the Full Year Ended March 31, 2023	26/23/26	CI
Supriya Lifescience Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	26/23/26	CI
Supriya Lifescience Limited Announces Resignation of Manoj Dorlikar as Whole Time Director	26/23/26	CI
Supriya Lifescience Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Supriya Lifescience Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 30, 2022	14/23/14	CI
Supriya Lifescience Appoints CFO	24/23/24	MT

Chart Supriya Lifescience Limited

Duration

Period

More charts

Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The Company's product portfolio consists of approximately 38 niche API products that address remedies in therapeutic segments, such as antihistamine, analgesic, vitamin, anesthetics and anti-asthmatics, among others. The Company has manufacturing facilities located in Maharashtra. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others.

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Supriya Lifescience Limited

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUPRIYA LIFESCIENCE LIMITED	+26.56%	39Cr
ELI LILLY AND COMPANY	+60.25%	85TCr
NOVO NORDISK A/S	+38.56%	63TCr
JOHNSON & JOHNSON	-4.49%	36TCr
MERCK & CO., INC.	+18.30%	32TCr
ABBVIE INC.	+9.64%	30TCr
ASTRAZENECA PLC	+14.15%	24TCr
ROCHE HOLDING AG	+3.11%	22TCr
NOVARTIS AG	+16.98%	22TCr
AMGEN INC.	+12.87%	17TCr

Other Pharmaceuticals